Table 1.
Characteristics of HIV-infected patients and healthy donors.
| Individuals | Gender | Current age | Contamination | Number of CD4+ T cells (cells/mm3) | CD4+ T cells nadir (cells/mm3) | Viral load (copie/ml) | Detection (age of patient) | Treatment started - Updated treatment | Current treatment | HCV co-infection |
|---|---|---|---|---|---|---|---|---|---|---|
| PAT-1 | Male | 54 | Sexual (Homo) | 543 | 204 | <40 | 1994 (32 years) | 1997–2015 | Tivicay Truvada | No |
| PAT-2 | Female | 54 | Sexual (Hetero) | 1376 | 167 | <40 | 1991 (26 years) | 1994–2014 | Isentress Kivexa | No |
| PAT-3 | Female | 70 | Sexual (Hetero) | 404 | 170 | <40 | 2001 (55 years) | 2008–2010 | Isentress Truvada | No |
| PAT-4 | Male | 51 | Sexual (Homo) | 1,451 | 130 | <40 | 1990 (24 years) | 1997–2013 | Kivexa Norvir Reyataz | No |
| PAT-5 | Male | 58 | Sexual (Hetero) | 324 | 13 | <40 | 2002 (43 years) | 2002–2016 | Kivexa Norvir Reyataz | No |
| PAT-6 | Male | 48 | Sexual (Homo) | 744 | 243 | <40 | 1991 (22 years) | 1998–2015 | Eviplera | No |
| HEA-1 | Male | 48 | ||||||||
| HEA-2 | Male | 63 | ||||||||
| HEA-3 | Female | 28 | ||||||||
| HEA-4 | Male | 59 | ||||||||
| HEA-5 | Male | 56 | ||||||||
| HEA-6 | Male | 56 | ||||||||
| HEA-7 | Female | 59 | ||||||||
| HEA-8 | Female | 25 | ||||||||
| HEA-9 | Male | 27 |
Information about the gender, current age, contamination pathway, viral load, year of detection of the HIV infection, starting year of the ARV treatment, updated year of the ARV treatment, type treatment, the duration of treatments, and the HCV co-infection status were provided for each HIV-infected patient. Information about the gender and the age were provided for each healthy donor. Information presented in this table corresponds to information obtained at the time of the blood samplings.